Turnover and Distribution of ¹³¹Iodine-Labelled Human Fibrinogen

Summary

14 patients (5 diabetics with arteriosclerotic complications, 4 patients with thrombo-embolic disease, 4 with cirrhosis, coagulation defects and increased fibrinolytic activity, and 1 cancer patient) and 3 control patients were subjected to turnover studies with ¹³iodine labelled human fibrinogen.

Half-life times in the control patients were found to be 4 days, the fractional turnover rates 19–23 per cent, of intravascular fibrinogen per day, and the absolute turnover 0.02 to 0.06 gm per day per kg. body weight. The other patient’s half-life times and turnover rates varied considerably from 0.9–5.5 days, 13–160 per cent, per day of intravascular fibrinogen and 0.02–0.4 gm per day per kg. body weight respectively.

As fibrinogen unlike other proteins subjected to turnover studies, is converted to fibrin, it is not possible to measure the true intra-extravascular distribution ratio of fibrinogen. But intravascular fibrinogen could be approximated to constitute 68–99 per cent, of the total fibrinogen. There is justification in believing that fibrinogen is degradated through a continuous coagulation in equilibrium with fibrinolysis, and that the organism contains a greater mass of fibrin, the “fibrin pool”. Considerations of the turnover mechanism can however only be hypothetical.

• References

• 1 Adelson E, Rheingold J. J, Parker O, Buenaventure A, Crosby CWH. Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood 18: 267 1961;
• 2 Albrechtsen O. K. Fibrinolytic activity in the organism. Universitetsforlaget i Aarhus (Denmark.). 1956
• 3 Amris C. J, Amris A. Investigations concerning activatorfree porcine plasmin. Scand. J. clin. Lab. Invest. 15: 189 1963;
• 4 Amris C. J, Larsen V, Mogensen B, Storm O. Infusion of porcine plasmin in man. Scand. J. clin. Lab. Invest. 15: 179 1963;
• 5 Andersen S. Bryde Simultaneously determination of plasma volume with ¹³^-labelled gamma-globulin, albumin and Evans Blue dye. Clin. Sci. 23: 221 1962;
• 6 Astrup T. The biological significance of fibrinolysis. Lancet. II: 565 1956;
• 7 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. 40: 346 1952;
• 8 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv for kemi. 10: 415 1956;
• 9 Christensen L. K. The turnover of plasma fibrinogen. Acta med. scand. 162: 407 1958;
• 10 Gitlin D, Borges W. H. Studies on the metabolism of fibrinogen in two patients with congenital afibrinogenaemia. Blood. 08: 679 1953;
• 11 Hammond JDS, Verel D. Observations on the distribution and biological half-life of human fibrinogen. Brit. J. Haemat. 05: 431 1959;
• 12 Jarnum S. A modified extraction method for determination of Evans Blue. Scand. J. clin. Lab. Invest. 11: 332 1959;
• 13 Laurell C. B, Laurell S, SJcoog N. Buffer composition in Paper electrophoresis. Considerations on its influence with special reference to the interaction between small ion and protein. Clin. Chem. 02: 99 1956;
• 14 Lewis J. H, Ferguson E. E, Schoenfeld G. Studies concerning the turnover of fibrino- gen-I¹³¹ in dog. J. Lab. clin. Med. 58: 247 1961;
• 15 Madden RER, Gould G. Turnover rate of plasma fibrinogen. Fed. Proc. 11: 252 1952;
• 16 McFarlane A. S. Efficient trace labelling of protein with iodine. Nature. 182: 53 1958;
• 17 MacFarlane A. S. In vivo behavior of 1¹³¹-fibrinogen. J. clin. Invest. 42: 346 1963;
• 18 Nilsson I. M, KrooJc H, Sternby N. H, Söderberg E, Söderström N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta med. Scand. 169: 323 1961;
• 19 Ollendorff P. Improvements in the thrombin generation test. Thrombos. Diathes haemorrh. (Stuttg.) 04: 244 1960;
• 20 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 03: 201 1951;
• 21 Paraskevas M, Nilsson I. M, Martinsson G. A method for determining serum inhibitor of plasminogen activation. Scand. J. clin. Lab. Invest. 14: 138 1962;
• 22 Pearson J. D, Veall N, Vetter H. A practical method for plasma albumin turnover studies. Radioaktive Isotope in Klinik und Forschung. 03: 290 1958;
• 23 Quick A. J. On quantitative estimation of prothrombin. Amer. J. clin Path. 15: 560 1945;
• 24 Rausen R. Aa, Cruchaud A, McMillan C. W, Gitlin D. A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia. Blood 18: 710 1961;